Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 4,225.0 | 4,089.0 | 3,115.0 | 4,032.0 | 3,980.9 | 4,939.0 | 5,270.9 | 4,689.1 |
| Revenue growth | 3.3% | 31.3% | -22.7% | 1.3% | -19.4% | -6.3% | 12.4% | 23.0% |
| Cost of goods sold | 193.0 | 216.0 | 210.0 | 206.0 | 217.3 | 209.8 | 117.0 | 2,937.7 |
| Gross profit | 4,032.0 | 3,873.0 | 2,905.0 | 3,826.0 | 3,763.5 | 4,729.2 | 5,153.9 | 1,751.4 |
| Gross margin | 95.4% | 94.7% | 93.3% | 94.9% | 94.5% | 95.8% | 97.8% | 37.4% |
| Selling, general and administrative | 814.0 | 810.0 | 707.0 | 850.0 | 845.5 | 816.1 | 945.8 | 795.3 |
| Research and development | 255.0 | 238.0 | 191.0 | 266.0 | 263.3 | 313.1 | 343.5 | 277.4 |
| EBITA | 1,110.0 | 1,098.0 | 437.0 | 822.0 | 830.4 | 1,064.4 | 1,218.2 | 1,039.7 |
| EBITA margin | 26.3% | 26.9% | 14.0% | 20.4% | 20.9% | 21.6% | 23.1% | 22.2% |
| Amortization of intangibles | 182.0 | 190.0 | 203.0 | 220.0 | 224.0 | 401.5 | 492.1 | 410.4 |
| EBIT | 928.0 | 908.0 | 234.0 | 602.0 | 606.4 | 662.9 | 726.1 | 629.3 |
| EBIT margin | 22.0% | 22.2% | 7.5% | 14.9% | 15.2% | 13.4% | 13.8% | 13.4% |
| Pre-tax income | 589.0 | 529.0 | -848.0 | 128.0 | 133.9 | -976.9 | 323.4 | -17.0 |
| Income taxes | 175.0 | 274.0 | 28.0 | 131.0 | 144.2 | -29.4 | 59.2 | 38.9 |
| Tax rate | 29.7% | 51.8% | | 102.3% | 107.7% | 3.0% | 18.3% | |
| Earnings from continuing ops | 414.0 | 255.0 | -1,751.0 | -2.0 | -10.3 | -947.5 | 264.2 | -55.9 |
| Earnings from discontinued ops | | 415.0 | 37.0 | 114.0 | 124.9 | | | |
| Net income | 414.0 | 670.0 | -1,714.0 | 112.0 | 114.6 | -947.5 | 264.2 | -55.9 |
| Net margin | 9.8% | 16.4% | -55.0% | 2.8% | 2.9% | -19.2% | 5.0% | -1.2% |
| |
| Diluted EPS | $2.04 | $1.23 | ($8.55) | ($9.79) | ($50.45) | ($4.66) | $1.31 | ($0.29) |
| Shares outstanding (diluted) | 203.4 | 206.8 | 204.7 | 0.2 | 0.2 | 203.1 | 202.2 | 192.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|